Protalix BioTherapeutics Reports Q3 2026 Revenue of $75.6 Million and Targets PRX-115 Phase II Results
Protalix BioTherapeutics (PLX) reported its financial results for the first nine months of 2026, announcing total revenues of $75.6 million. The company concluded the quarter with a cash position of $48.5 million in cash and deposits, which management intends to use to fund ongoing clinical development. A primary focus for the company is its lead candidate, PRX-115, with top-line results from Phase II clinical trials expected in the second half of next year. Protalix is positioning itself within the Fabry disease market, which it projects will reach a valuation of $3.2 billion by 2031.
